Cost-Effectiveness Analysis of Prophylactic Cervical Cancer Vaccination in Japanese Women

Konno, Ryo; Sasagawa, Toshiyuki; Fukuda, Takashi; Kriekinge, Georges Van; Demarteau, Nadia

doi:10.1111/igc.0b013e3181d189b8

Cited by 22 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Konno et al (2010) Although we contemplated that this discrepancy may have resulted from between-country differences (Galante et al, 2011), bias may have arisen from the different details of the scenarios that were used in each study. Indeed, such between-scenario differences are always and issue for hypothetical evaluations.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Murasawa¹,

Konno²,

Okubo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Murasawa¹,

Konno²,

Okubo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

“…The Markov model was adapted from previously published models by Debicki [21] and Konno [22] and has been used to perform cost-effectiveness analyses in other countries such as Canada, Taiwan and Japan. The model simulated the natural history of cervical cancer (extending from infection to death) in the hypothetical cohort of 12-year-old girls who are vaccinated in addition to current screening or screening only for cervical cancer, with follow up for a life-time.…”

Section: Methodsmentioning

confidence: 99%

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China

Zhang

Liu

et al. 2016

BMC Cancer

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) 16 and 18 are the two most common HPV oncogenic types that can be prevented by vaccination. This study aimed at assessing the cost-effectiveness of 3 doses of the bivalent HPV vaccine in rural and urban settings in China.MethodsA Markov model was adapted to reflect the lifetime of a modelled 100,000 12-year-old girls cohort in rural and urban settings in China. Input parameters were obtained from published literature, official reports and a two-round expert review panel. Clinical and economic outcomes of vaccination at age 12 with screening was compared to screening only. In the base case analysis, a 3 % discount rate, the vaccine cost of 247 CNY (US$ 39, PAHO vaccine cost in 2013), two rounds of screening in a life time and 70 % coverage for both screening and vaccination were used. One-way, two-way and probabilistic sensitivity analyses were performed. We used different thresholds of cost-effectiveness to reflect the diversity of economic development in China.ResultsVaccination in addition to screening could prevent 60 % more cervical cancer cases and deaths than screening only. The incremental cost effectiveness ratio varied largely when changing cost of vaccination and discount in one way analysis. Vaccination was very cost-effective when the vaccine cost ranged 87-630 CNY (US$ 13.8-100) in rural and 87-750 CNY (US$ 13.8–119) in urban; and remained cost-effective when the vaccine cost ranged 630–1,700 CNY (US$ 100–270) in rural and 750–1,900 CNY (US$ 119–302) in urban in two way analysis. Probabilistic sensitivity analyses showed that model results were robust.ConclusionsIn both rural and urban, the vaccination cost and discounting are important factors determining the cost-effectiveness of HPV vaccination; policy makers in China should take these into account when making a decision on the introduction of HPV vaccine. In areas with a high burden of cervical cancer and limited screening activities, HPV vaccination should be prioritized. However, the vaccine cost needs to be reduced in order to make it very cost-effective and affordable as well, in particular in poverty areas with high disease burden.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2893-x) contains supplementary material, which is available to authorized users.

show abstract

“…To date there has been only one study that has assessed the impact of introducing HPV vaccine in Japan 16 . However, this study suffered from several major limitations.…”

Section: Discussionmentioning

confidence: 99%

“…Only one study has evaluated the cost‐effectiveness of HPV vaccination in the Japanese setting 16 . However, the study did not compare strategies with a variable screening rate.…”

Section: Introductionmentioning

confidence: 99%

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost‐effectiveness analysis

Yamamoto

Mori²,

Jacklin

et al. 2011

BJOG

View full text Add to dashboard Cite

Objective To assess the cost-effectiveness of universal vaccination of 11-year-old girls against human papillomavirus (HPV) infection and increased screening coverage to prevent cervical cancer in Japan where the coverage of Papanicolaou smears is very low.Design A cost-utility analysis from a societal perspective.Setting Japan, 2010.Population The female Japanese population aged 11 years or older.Methods A Markov model of the natural history of cervical cancer was constructed to compare six strategies: i.e. a screening coverage rate of 20, 50 and 80% with and without routine vaccination at age 11.Main outcome measures Cervical cancer incidence, qualityadjusted life years (QALYs), costs and incremental costeffectiveness ratios.Results Expanding the coverage of Papanicolaou smears from the current level of 20-50 and 80% yields a 45.5 and 63.1% reduction in cervical cancer incidence, respectively. Impact of combined strategies increases with coverage. Coverages of 20, 50 and 80% showed a 66.1, 80.9 and 86.8% reduction in disease, respectively. The costs of strategies with vaccination are four times higher than the cost of strategies without vaccination. Vaccinating all 11-yearold girls with bivalent vaccines with a Papanicolaou smear coverage rate of 50% is likely to be the most cost-effective option among the six strategies.Conclusions The introduction of HPV vaccination in Japan is cost-effective as in other countries. It is more cost-effective to increase the coverage of the Papanicolaou smear along with the universal administration of HPV vaccine.

show abstract

Cost-Effectiveness Analysis of Prophylactic Cervical Cancer Vaccination in Japanese Women

Abstract: The implementation of a CC vaccination in Japan could reduce the CC burden in a very cost-effective manner for women up to 45 years.

Cited by 22 publications

References 15 publications

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost‐effectiveness analysis

Contact Info

Product

Resources

About